Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter P Koopmans

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
AIDS (London, England)|December 29, 2004
F-18-fluorodeoxyglucose positron emission tomography for visualization of lipodystrophy in HIV-infected patientsChantal P Bleeker-Rovers, André J van der Ven, Bert Zomer, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2002
International interlaboratory quality control program for measurement of antiretroviral drugs in plasmaRob E Aarnoutse, Corrien P W G M Verweij-van Wissen, Eleonora W J van Ewijk-Beneken Kolmer, et al.
AIDS (London, England)|April 11, 2006
The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapyJolanda G M Hoefnagel, Manon J van der Lee, Peter P Koopmans, et al.
Therapeutic Drug Monitoring|December 31, 2010
Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrationsSerena Slavenburg, Hanneke W H A Huntjens-Fleuren, Ton S M Dofferhoff, et al.
Clinical Pharmacology and Therapeutics|August 8, 2006
Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjectsManon J van der Lee, Lara Dawood, Hadewych J M ter Hofstede, et al.
Plos One|July 16, 2011
Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolatesFranky Baatz, Monique Nijhuis, Morgane Lemaire, et al.
The Journal of Antimicrobial Chemotherapy|November 25, 2010
Efavirenz concentrations in CSF exceed IC50 for wild-type HIVBrookie M Best, Peter P Koopmans, Scott L Letendre, et al.
Basic & Clinical Pharmacology & Toxicology|March 12, 2008
Evaluation of cytotoxic, genotoxic and CYP450 enzymatic competition effects of Tanzanian plant extracts traditionally used for treatment of fungal infectionsCarolien J P van den Bout-van den Beukel, Omar J M Hamza, Mainen J Moshi, et al.
AIDS Research and Human Retroviruses|October 22, 2008
Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapyCarolien J P Van Den Bout-Van Den Beukel, Lydia Fievez, Meta Michels, et al.
Therapeutic Drug Monitoring|June 24, 2015
Lower Ribavirin Plasma Concentrations in HCV/HIV-Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar DosageMaarten J Deenen, Clara T M M de Kanter, Anthonius S M Dofferhoff, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
AIDS (London, England)|December 29, 2004
F-18-fluorodeoxyglucose positron emission tomography for visualization of lipodystrophy in HIV-infected patientsChantal P Bleeker-Rovers, André J van der Ven, Bert Zomer, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2002
International interlaboratory quality control program for measurement of antiretroviral drugs in plasmaRob E Aarnoutse, Corrien P W G M Verweij-van Wissen, Eleonora W J van Ewijk-Beneken Kolmer, et al.
AIDS (London, England)|April 11, 2006
The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapyJolanda G M Hoefnagel, Manon J van der Lee, Peter P Koopmans, et al.
Therapeutic Drug Monitoring|December 31, 2010
Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrationsSerena Slavenburg, Hanneke W H A Huntjens-Fleuren, Ton S M Dofferhoff, et al.
Clinical Pharmacology and Therapeutics|August 8, 2006
Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjectsManon J van der Lee, Lara Dawood, Hadewych J M ter Hofstede, et al.
Plos One|July 16, 2011
Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolatesFranky Baatz, Monique Nijhuis, Morgane Lemaire, et al.
The Journal of Antimicrobial Chemotherapy|November 25, 2010
Efavirenz concentrations in CSF exceed IC50 for wild-type HIVBrookie M Best, Peter P Koopmans, Scott L Letendre, et al.
Basic & Clinical Pharmacology & Toxicology|March 12, 2008
Evaluation of cytotoxic, genotoxic and CYP450 enzymatic competition effects of Tanzanian plant extracts traditionally used for treatment of fungal infectionsCarolien J P van den Bout-van den Beukel, Omar J M Hamza, Mainen J Moshi, et al.
AIDS Research and Human Retroviruses|October 22, 2008
Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapyCarolien J P Van Den Bout-Van Den Beukel, Lydia Fievez, Meta Michels, et al.
Therapeutic Drug Monitoring|June 24, 2015
Lower Ribavirin Plasma Concentrations in HCV/HIV-Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar DosageMaarten J Deenen, Clara T M M de Kanter, Anthonius S M Dofferhoff, et al.
Pageof 5